STOCK TITAN
  1. Home
  2. News
  3. OLMA

Olema Pharmaceuticals, Inc. - OLMA STOCK NEWS

Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.

Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company advancing targeted therapies for endocrine-driven breast cancers. This page provides investors and healthcare professionals with timely updates on clinical developments, financial disclosures, and strategic initiatives.

Access consolidated information about OLMA's lead candidate palazestrant (OP-1250), an oral complete estrogen receptor antagonist/SERD, and other pipeline assets like the KAT6 inhibitor OP-3136. Track regulatory milestones, partnership announcements, and peer-reviewed research findings in one centralized location.

Key updates include clinical trial progress, scientific conference presentations, and financial results. All content is sourced from official company communications and verified industry reports to ensure accuracy.

Bookmark this page for streamlined access to OLMA's latest developments in women's oncology therapeutics. Check regularly for essential updates impacting treatment innovation and corporate strategy.

News

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Olema Pharmaceuticals, Inc. granted stock options to four new employees to purchase 33,600 shares of common stock, effective February 1, 2024. The options vest over four years, with a 10-year term and an exercise price of $15.25 per share. This move is in accordance with the 2022 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
News

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Rhea-AI Summary
Olema Pharmaceuticals, Inc. (OLMA) announced the selection of a development candidate, OP-3136, for the Company’s program targeting KAT6, an epigenetic target dysregulated in breast cancer and other cancers. The compound has demonstrated potent anti-tumor activity and is set to advance into clinical development by the end of 2024. OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor developed in collaboration with Aurigene Oncology. The company presented promising data at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, showing highly selective and potent activity against KAT6A and KAT6B in ER+ breast cancer cell lines. Olema is initiating non-clinical Investigational New Drug (IND) enabling studies to support a potential IND submission to the FDA for OP-3136 by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
none
-
News

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Olema Pharmaceuticals, Inc. (OLMA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
conferences
News

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Rhea-AI Summary
Olema Pharmaceuticals, Inc. (OLMA) announced positive interim results from a Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitors ribociclib and palbociclib. The company also outlined the trial design for the ongoing Phase 3 OPERA-01 monotherapy trial and announced the activation of clinical sites and initiation of patient dosing. Olema will host an investor conference call on December 6, 2023, to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.34%
Tags
clinical trial
-
News

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) granted stock options to three new employees, allowing them to purchase 57,500 shares of the Company's common stock. The options vest over four years, with an exercise price of $14.58 per share, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.34%
Tags
none
-
News

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Rhea-AI Summary
Olema Pharmaceuticals, Inc. (OLMA) will present new Phase 1b/2 clinical data of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib and palbociclib at the San Antonio Breast Cancer Symposium on December 7, 2023. The company will also host an investor conference call on December 8, 2023, to review the data presented at the symposium and ongoing studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
conferences clinical trial
News

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
OLMA: Olema Pharmaceuticals Reports Strong Cash Position of $276.9M, Phase 3 Trial Progress, and Presentation at SABCS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
earnings
-
News

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Olema Pharmaceuticals, Inc. granted stock options to two new employees, allowing them to purchase a total of 85,000 shares of the company's common stock. The options vest over four years, with 25% vesting on the first anniversary and the rest vesting in 36 equal monthly installments. The options have a 10-year term and an exercise price of $14.94 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.4%
Tags
none
-
News

Olema Oncology to Participate in Upcoming Investor Conferences in November

Rhea-AI Summary
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, will be presenting at two investor conferences in November. The company's President and CEO, Dr. Sean P. Bohen, will participate in Fireside Chats at the Jefferies London Healthcare Conference on November 15 and the Evercore ISI HealthCONx Conference on November 29. The webcasts of the Fireside Chats will be available on Olema's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.35%
Tags
conferences
News

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Rhea-AI Summary
Olema Pharmaceuticals announces positive results from a Phase 2 clinical study of palazestrant for the treatment of metastatic ER+/HER2- breast cancer. The study showed a median progression-free survival of 4.6 months and a clinical benefit rate of 40% across all patients. In patients with ESR1 mutations, the median progression-free survival was 5.6 months with a clinical benefit rate of 52%. Olema plans to initiate a Phase 3 clinical trial for palazestrant in second- and third-line metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Stock OLMA logo
Olema Pharmaceuticals, Inc.

Nasdaq:OLMA

OLMA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

OLMA Stock Data

302.03M
65.55M
3.21%
101.58%
11.4%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO